<DOC>
	<DOC>NCT00988312</DOC>
	<brief_summary>Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.</brief_summary>
	<brief_title>Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>multiple myeloma stage I (Salmon &amp; Durie) no cytoreductive pretreatment myeloma stages IIIII asecretory disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>dendritic cells (DC)</keyword>
	<keyword>idiotype (Id)</keyword>
	<keyword>immunotherapy</keyword>
</DOC>